– Professor Alan Ashworth, Institute of Cancer Research chief executive
We are delighted by today's decision to allow patients with advanced prostate cancer to receive abiraterone on the NHS.
This drug was discovered at the Institute of Cancer Research and is the result of more than two decades of dedicated work by our scientists and and collaborators.
In clinical trials of men with advanced prostate cancer who have already tried chemotherapy, it has been shown to extend life by an average of four months and improve quality of life.
The National Institute for Health and Clinical Excellence (Nice) has revised its recommendations on a drug to treat advanced prostate cancer. The institute now says Abirateron, marketed as Zytiga, should be given to patients on the NHS.